Orchid Pharma Reports 12% Revenue Growth in Q2, Completes Strategic Acquisitions

Orchid Pharma Limited , a prominent player in the pharmaceutical sector, has reported its unaudited standalone financial results for the second quarter, indicating revenue growth and strategic expansions.

Financial Performance

The company's Q2 results reveal a positive trend compared to the previous quarter:

Metric (in ₹ crore)	Q2	Q1	QoQ Change
Net Sales	193.52	172.93	+11.91%
Profit Before Tax	20.23	204.29	-90.10%

Orchid Pharma reported standalone net sales of ₹193.52 crore for the quarter, compared to ₹172.93 crore in the previous quarter, marking a growth of 11.91% in revenue.

Profitability

The company achieved a standalone profit before tax of ₹20.23 crore for the current quarter. This represents a decrease from the previous quarter's ₹204.29 crore.

Earnings Per Share

Basic earnings per share stood at ₹0.44 for the quarter.

Strategic Acquisitions

Orchid Pharma has expanded its global presence and product portfolio through recent acquisitions:

Completed acquisitions of 100% assets of Alectra Therapeutics GmbH, Germany and Alectra Therapeutics SAS, France, gaining global ownership of the Enmetazobactam antibiotic molecule.
Acquired 100% share capital of Weichensee 1272 VV GmbH, Germany, which has been renamed as Orchid Pharma Europe GmbH.

Corporate Developments

The Board of Directors approved the unaudited financial results in a meeting held on November 11.
The company has submitted a petition for amalgamation with its holding company Dhanuka Laboratories Limited to the National Company Law Tribunal, Chennai bench.

Conclusion

With recent strategic acquisitions and revenue growth, Orchid Pharma appears to be positioning itself for expansion. The company's ability to integrate these new assets and capitalize on the global ownership of the Enmetazobactam antibiotic molecule may be crucial for its future performance.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.53%	-3.80%	+9.60%	+0.43%	-45.00%	+2,934.98%

Orchid Pharma has successfully completed the acquisition of assets from Allecra Therapeutics GmbH, a significant move in the pharmaceutical sector. The company made this announcement to the National Stock Exchange of India (NSE) and BSE Limited on October 30, 2025.

Key Details of the Acquisition

Aspect	Details
Transaction Completion Date	October 29, 2025
Initial Announcement Date	July 30, 2025
Assets Acquired	All intellectual property and commercial contracts of Allecra Therapeutics GmbH
Regulatory Compliance	Disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Implications of the Acquisition

The successful closure of this deal marks a significant milestone for Orchid Pharma. By acquiring Allecra Therapeutics' assets, Orchid Pharma has expanded its intellectual property portfolio and commercial reach. This strategic move may potentially strengthen Orchid Pharma's position in the pharmaceutical market and could lead to new opportunities for growth and innovation.

Corporate Disclosure

Orchid Pharma has maintained transparency throughout the acquisition process, keeping investors and stakeholders informed. The company's prompt disclosure to the stock exchanges demonstrates its commitment to regulatory compliance and shareholder communication.

Kapil Dayya, Company Secretary & Compliance Officer of Orchid Pharma Limited, signed off on the official communication to the stock exchanges, ensuring adherence to corporate governance standards.

As the pharmaceutical landscape continues to evolve, this acquisition may be viewed as part of Orchid Pharma's strategy to enhance its market presence and capabilities. Investors and industry observers may want to keep an eye on how Orchid Pharma integrates these newly acquired assets into its existing operations and the potential impact on the company's future performance.